(23%). Over the two study periods, a smaller proportion of patients on bosentan than on placebo required epoprostenol therapy (2.8% versus 4.3%), additional therapy for PAH (28.6% versus 38.5%), or hospitalization (4.2% versus 13.0% for PAH-related and 16.0% versus 23.2% for all causes of hospitalization).
Purpose: Folic acid has favourable effects on vascular endothelium and lowers plasma homocysteine levels. In addition, homocysteine appears to be an independent risk factor for atherosclerotic disease. However, the value of folic acid in secondary prevention had seldom been tested. Two yr folic acid treatment in the randomized GOES study showed no reduction in clinical endpoints despite a 18% homocysteine reduction in patients on folic acid. Suggested was that the follow up could have been too short, therefore the study was extended with another 18 months Tx. Here we report results of the extended Goes trial, an open-label trial with folic acid 0.5 mg per day in a patient population with stable coronary artery disease (CAD). Methods: 593 Patients were included in this study; 300 were randomized to folic acid and 293 served as controls. Mean follow-up time was 42 months. At baseline all patients had been on statin therapy for a mean of 3.2 years. Results: In patients treated with folic acid plasma homocysteine levels decreased with 18% from 12.0 ± 4.8 to 9.4 ± 3.5 µmol/L, while these levels remained unaffected in the control group (p <0.001 between groups). The primary endpoint (all-cause mortality and a composite of vascular events) was encountered in 75 (25.0%) patients in the folic acid group and in 75 (25.6%) patients in the control group (RR 0.98; p=NS) . Also in the quartile of patients with the highest baseline homocysteine levels (>13.7 micromol/L) no salutary effects of folic acid Tx could be demonstrated. In a multifactorial survival model with adjustments for clinical factors the most predictive laboratory parameters were, in order of significance, levels of creatinine clearance, and homocysteine. Conclusions: Within 3.5 years folic acid does not seem to reduce clinical endpoints in patients with stable CAD while on statin treatment. Homocysteine might therefore merely be a marker of disease than a causal risk factor. Thus, until more trials will become available, low dose folic acid supplementation should be treated with reservation. Methods: Intracoronary ultrasound automated pull-backs were recorded on S-VHS tape both before and after twelve months of lipid-lowering therapy in a target coronary artery in 18 subjects with known coronary artery disease. The pullbacks were digitized and calibrated, and identical segments with plaque in the target artery were identified on the preand post-therapy images. The lumen and adventitia-media borders were manually traced on all images in the segment that allowed image interpretation, with the longitudinal position noted. The plaque and adventitial volumes were calculated by a numerical integration of the area over the longitudinal length. The mean plaque adventitial, and lumen areas in sq. mm were calculated based on plaque and adventitial volume and segment length.
Results:
The change in mean lumen area was poorly correlated with the change in mean plaque area (R = 0.256, p = 0.306). Lumen area change was strongly correlated with adventitial area change (R = 0.903, p <0.001, see figure below) The relationship was Change in mean lumen area = 0.712 x Change in mean adventitial area + 0.347 mm2.
Conclusions:
The changes in lumen area after one year of lipid-lowering therapy are better correlated with adventitial change than with plaque change, indicating that arterial remodeling is an important determinant of lumen change.
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